Strain-Independent Therapeutic Antibodies for Influenza

描述（由申请人提供）：用于鉴定对多种抗原具有高特异性和亲和力的罕见人抗体的Trellis Bioscience的CellSpot技术使得能够发现针对呼吸道合胞病毒和巨细胞病毒的高度有效的菌株非依赖性抗体。我们现在已经应用CellSpot分离了两种分别对组1和组2甲型流感病毒株具有广泛反应性的天然人抗体。这两种抗体现已显示具有体内功效。此外，我们还分离出了一种具有体外抗流感B活性的人抗体。我们建议将这些治疗候选药物推进到IND阶段，包括额外的体外中和研究， 体内、生产、毒性和PK研究。预计最终的临床候选人将 对所有目前流行的毒株提供有效的感染后抗病毒活性，并对任何新出现的大流行毒株提供有效的预防。

DESCRIPTION (provided by applicant): Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group 1 and Group 2 influenza A strains respectively. Both of these antibodies have now been shown to have in vivo efficacy. In addition, we have isolated a human antibody with in vitro activity against Influenza B. We propose to advance these therapeutic candidates to IND stage, including additional neutralization studies in vitro and in vivo, manufacturing, toxicity, and PK studies. The resulting clinical candidates are expected to provide potent post-infection antiviral activity against all currently circulating strains, and effective prophylaxis against any emerging pandemic strain.